|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambros RA and Kurman RJ: Current concepts
in the relationship of human papillomavirus infection to the
pathogenesis and classification of precancerous squamous lesions of
the uterine cervix. Semin Diagn Pathol. 7:158–172. 1990.PubMed/NCBI
|
|
4
|
Xiao D, Huang W, Ou M, Guo C, Ye X, Liu Y,
Wang M, Zhang B, Zhang N, Huang S, et al: Interaction between
susceptibility loci in cGAS-STING pathway, MHC gene and HPV
infection on the risk of cervical precancerous lesions in Chinese
population. Oncotarget. 7:84228–84238. 2016.PubMed/NCBI
|
|
5
|
Nieves-Ramirez ME, Partida-Rodriguez O,
Alegre-Crespo PE, Tapia-Lugo Mdel C and Perez-Rodriguez ME:
Characterization of single-nucleotide polymorphisms in the tumor
necrosis factor alpha promoter region and in lymphotoxin α in
squamous intraepithelial lesions, precursors of cervical cancer.
Transl Oncol. 4:336–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bodily J and Laimins LA: Persistence of
human papillomavirus infection: Keys to malignant progression.
Trends Microbiol. 19:33–39. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castle PE, Schiffman M, Wheeler CM and
Solomon D: Evidence for frequent regression of cervical
intraepithelial neoplasia-grade 2. Obstet Gynecol. 113:18–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi A, Weinberg V, Darragh T and
Smith-McCune K: Evolving immunosuppressive microenvironment during
human cervical carcinogenesis. Mucosal Immunol. 1:412–420. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Wang L, Li B, Huo M, Mu M, Liu J
and Han J: miR-145 downregulates the expression of cyclin-dependent
kinase 6 in human cervical carcinoma cells. Exp Ther Med.
8:591–594. 2014.PubMed/NCBI
|
|
10
|
Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J,
Lu W, Wan X, Ma D and Xie X: Progressive miRNA expression profiles
in cervical carcinogenesis and identification of HPV-related target
genes for miR-29. J Pathol. 224:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Meyers C, Guo M and Zheng ZM:
Upregulation of p18Ink4c expression by oncogenic HPV E6 via
p53-miR-34a pathway. Int J Cancer. 129:1362–1372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sridhar J, Akula N and Pattabiraman N:
Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS
J. 8:E204–E221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tadano T, Kakuta Y, Hamada S, Shimodaira
Y, Kuroha M, Kawakami Y, Kimura T, Shiga H, Endo K, Masamune A, et
al: MicroRNA-320 family is downregulated in colorectal adenoma and
affects tumor proliferation by targeting CDK6. World J Gastrointest
Oncol. 8:532–542. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee AR, Park J, Jung KJ, Jee SH and
Kim-Yoon S: Genetic variation rs7930 in the miR-4273-5p target site
is associated with a risk of colorectal cancer. Onco Targets Ther.
9:6885–6895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng N, Yang P, Wang Z and Zhou Q:
OncomicroRNAs-mediated tumorigenesis: Implication in cancer
diagnosis and targeted therapy. Curr Cancer Drug Targets. 17:40–47.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nayar R and Wilbur DC: The Pap test and
Bethesda 2014. Cancer Cytopathol. 123:271–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yi X, Li J, Yu S, Zhang A, Xu J, Yi J, Zou
J, Nie X, Huang J and Wang J: A new PCR-based mass spectrometry
system for high-risk HPV, part I: Methods. Am J Clin Pathol.
136:913–919. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qu S, Huang J, Zhao J, Zhao X, Deng H,
Yang H, Chen W, Liu L, Zhang L and Gao S: A comparison of
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry and surface plasmon resonance for genotyping of
high-risk human papillomaviruses. Intervirology. 54:326–332. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jurinke C, van den Boom D, Cantor CR and
Köster H: Automated genotyping using the DNA MassArray technology.
Methods Mol Biol. 187:179–192. 2002.PubMed/NCBI
|
|
20
|
Hahn LW, Ritchie MD and Moore JH:
Multifactor dimensionality reduction software for detecting
gene-gene and gene-environment interactions. Bioinformatics.
19:376–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heidema AG, Feskens EJ, Doevendans PA,
Ruven HJ, van Houwelingen HC, Mariman EC and Boer JM: Analysis of
multiple SNPs in genetic association studies: Comparison of three
multi-locus methods to prioritize and select SNPs. Genet Epidemiol.
31:910–921. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tunesi S, Ferrante D, Mirabelli D, Andorno
S, Betti M, Fiorito G, Guarrera S, Casalone E, Neri M, Ugolini D,
et al: Gene-asbestos interaction in malignant pleural mesothelioma
susceptibility. Carcinogenesis. 36:1129–1135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Andersson T, Alfredsson L, Källberg H,
Zdravkovic S and Ahlbom A: Calculating measures of biological
interaction. Eur J Epidemiol. 20:575–579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muthuri SG, Doherty S, Zhang W, Maciewicz
RA, Muir KR and Doherty M: Gene-environment interaction between
body mass index and transforming growth factor beta 1 (TGFβ1) gene
in knee and hip osteoarthritis. Arthritis Res Ther. 15:R522013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knol MJ, van der Tweel I, Grobbee DE,
Numans ME and Geerlings MI: Estimating interaction on an additive
scale between continuous determinants in a logistic regression
model. Int J Epidemiol. 36:1111–1118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Knol MJ, VanderWeele TJ, Groenwold RH,
Klungel OH, Rovers MM and Grobbee DE: Estimating measures of
interaction on an additive scale for preventive exposures. Eur J
Epidemiol. 26:433–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai X, Li L, Liu X, Hu W, Yang Y and Bai
Z: Cooperation of DLC1 and CDK6 affects breast cancer clinical
outcome. G3 (Bethesda). 5:81–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia B, Yang S, Liu T and Lou G: miR-211
suppresses epithelial ovarian cancer proliferation and cell-cycle
progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li LP, Wu WJ, Sun DY, Xie ZY, Ma YC and
Zhao YG: miR-449a and CDK6 in gastric carcinoma. Oncol Lett.
8:1533–1538. 2014.PubMed/NCBI
|
|
30
|
Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng
X, Chen H, Jin J, Peng C, Li H and Shen B: Downregulation of gas5
increases pancreatic cancer cell proliferation by regulating CDK6.
Cell Tissue Res. 354:891–896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arvanitis DA and Spandidos DA:
Deregulation of the G1/S phase transition in cancer and squamous
intraepithelial lesions of the uterine cervix: A case control
study. Oncol Rep. 20:751–760. 2008.PubMed/NCBI
|
|
32
|
Choi YJ and Anders L: Signaling through
cyclin D-dependent kinases. Oncogene. 33:1890–1903. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Costello JF, Plass C, Arap W, Chapman VM,
Held WA, Berger MS, Su Huang HJ and Cavenee WK: Cyclin-dependent
kinase 6 (CDK6) amplification in human gliomas identified using
two-dimensional separation of genomic DNA. Cancer Res.
57:1250–1254. 1997.PubMed/NCBI
|
|
34
|
Zhou X, Chen X, Hu L, Han S, Qiang F, Wu
Y, Pan L, Shen H, Li Y and Hu Z: Polymorphisms involved in the
miR-218-LAMB3 pathway and susceptibility of cervical cancer, a
case-control study in Chinese women. Gynecol Oncol. 117:287–290.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reshmi G, Surya R, Jissa VT, Babu PS,
Preethi NR, Santhi WS, Jayaprakash PG and Pillai MR: C-T variant in
a miRNA target site of BCL2 is associated with increased risk of
human papilloma virus related cervical cancer-an in silico
approach. Genomics. 98:189–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi TY, Cheng X, Yu KD, Sun MH, Shao ZM,
Wang MY, Zhu ML, He J, Li QX, Chen XJ, et al: Functional variants
in TNFAIP8 associated with cervical cancer susceptibility and
clinical outcomes. Carcinogenesis. 34:770–778. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Giuliano AR, Sedjo RL, Roe DJ, Harri R,
Baldwi S, Papenfuss MR, Abrahamsen M and Inserra P: Clearance of
oncogenic human papillomavirus (HPV) infection: Effect of smoking
(United States). Cancer Causes Control. 13:839–846. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Syrjänen K, Shabalova I, Petrovichev N,
Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G,
Sozaeva L, Lipova E, et al: Age at menarche is not an independent
risk factor for high-risk human papillomavirus infections and
cervical intraepithelial neoplasia. Int J STD AIDS. 19:16–25. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moscicki AB, Winkler B, Irwin CE Jr and
Schachter J: Differences in biologic maturation, sexual behavior,
and sexually transmitted disease between adolescents with and
without cervical intraepithelial neoplasia. J Pediatr. 115:487–493.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Muñoz N, Franceschi S, Bosetti C, Moreno
V, Herrero R, Smith JS, Shah KV, Meijer CJ and Bosch FX;
International Agency for Research on Cancer, ; Multicentric
Cervical Cancer Study Group, : Role of parity and human
papillomavirus in cervical cancer: The IARC multicentric
case-control study. Lancet. 359:1093–1101. 2002. View Article : Google Scholar : PubMed/NCBI
|
